Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Accumulated Expenses (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Accumulated Expenses for 16 consecutive years, with $2.1 million as the latest value for Q2 2025.

  • On a quarterly basis, Accumulated Expenses fell 10.91% to $2.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $2.1 million, a 10.91% decrease, with the full-year FY2024 number at $318000.0, down 5.36% from a year prior.
  • Accumulated Expenses was $2.1 million for Q2 2025 at Harvard Bioscience, up from $318000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.2 million in Q1 2024 to a low of $228000.0 in Q3 2021.
  • A 5-year average of $1.5 million and a median of $1.2 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 89.72% in 2021, then skyrocketed 1255.7% in 2022.
  • Harvard Bioscience's Accumulated Expenses stood at $240000.0 in 2021, then grew by 11.67% to $268000.0 in 2022, then grew by 25.37% to $336000.0 in 2023, then decreased by 5.36% to $318000.0 in 2024, then surged by 567.92% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Accumulated Expenses are $2.1 million (Q2 2025), $318000.0 (Q4 2024), and $2.4 million (Q2 2024).